Here's Why ArtiCure, Inc. Is Up Double-Digits Today

By Brian

What happened

Continue Reading Below

In response to reporting upbeat first-quarter earnings, shares of ArtiCure(NASDAQ: ATRC),a medical device maker focused on cardiovascular products, rose more than 10% as of 11:45 a.m. EST on Friday.

So what

Here's a look at the headline numbers that lead to Friday's price action:

More From

  • Revenue grew 15% to $41.3 million. This figure compared favorably to the$40.3 million in revenue Wall Street had expected.
  • U.S. revenue grew by 18%, while international sales increased just 4%.
  • Gross margin expanded by 60 basis points year over year to 72.7%.
  • Net loss was $10.2 million, or $0.32 per share. This result also came in ahead of the $0.35 loss analysts had predicted.
  • Cash balance at quarter end was $34.5 million.

The better-than-expected quarterly results caused traders to cheer.

Image source: Getty Images.

Now what

Looking ahead, management reiterated its full-year 2017 guidance, which calls for revenue to land between $175 million to $178 million. That represents top-line growth of approximately 13% to 15% year over year. Turning to the bottom line, the company expects to produce a net lossin the range of$0.94 to $1.04 per share.

While the markets are applauding ArtiCure's results, it's worth pointing out that the company continues to bleed capital and is expected to do so for the near future. Given that its cash balance is getting low, it's possible the company might be forced to tap shareholders for extra cash in the not-too-distant future. For that reason, I'd suggest to potential shareholders that they simply monitor this company's progress from the sidelines.

10 stocks we like better than AtriCureWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and AtriCure wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of May 1, 2017.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.